Network origin in Victor Stone first degree
Entity | Entity type | Industry | |
---|---|---|---|
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation.
9
| Holding Company | Biotechnology | 9 |
Adaptate Biotherapeutics Ltd.
Adaptate Biotherapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Adaptate Biotherapeutics Ltd. engages in research and experimental development on biotechnology. The company was founded on August 21, 2019 and is headquartered in London, the United Kingdom.
5
| Subsidiary | Miscellaneous Commercial Services | 5 |
Takeda Ventures, Inc.
Takeda Ventures, Inc. Investment ManagersFinance Takeda Ventures Inc (Takeda Ventures) is a venture capital subsidiary of Takeda America Holdings Inc founded in 2001. The firm is headquartered in Palo Alto, California.
4
| Subsidiary | Investment Managers | 4 |
Whiz Partners, Inc.
Whiz Partners, Inc. Investment ManagersFinance Whiz Partners, Inc. (Whiz Partners) is an independent venture capital firm headquartered in Tokyo, Japan. It became a separate entity from its former brand, CSK Venture Capital Co., Ltd. The firm was founded by Toshio Ando, Atsushi Matsumura, and Junichi Kajimoto in 2010.
3
| Private Company | Investment Managers | 3 |
ARTham Therapeutics, Inc.
ARTham Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Kaken Pharmaceutical Co., Ltd., ARTham Therapeutics, Inc. is a pharmaceutical company based in Yokohama, Japan. The Japanese company's mission is to deliver "medicines that matter" to improve patient health and contribute to enhanced quality of life through the development of innovative disease-modifying medicines. The company was founded by Sham Nikam, Naoto Uemura, and has been led by CEO Hiroshi Nagabukuro since 2018. ARTham Therapeutics was acquired by Kaken Pharmaceutical Co., Ltd. on December 13, 2021 for $111.95 million.
3
| Subsidiary | Pharmaceuticals: Major | 3 |
Axcelead Drug Discovery Partners, Inc.
Axcelead Drug Discovery Partners, Inc. Miscellaneous Commercial ServicesCommercial Services Axcelead Drug Discovery Partners, Inc. is a Japanese company founded in 2017 that provides services for the quality evaluation of new modality regenerative medical cells, effectiveness and safety evaluation of target cells, and bridging data. The company is based in Fujisawa, JP. and has subsidiaries in the United States. It is used by more than 100 facilities such as clients pharmaceutical companies, venture companies, and academia. Axcelead offers non-clinical development strategic planning and problem resolution services to its clients.
1
| Holding Company | Miscellaneous Commercial Services | 1 |
IgniteEye Corp.
IgniteEye Corp. Packaged SoftwareTechnology Services IgniteEye Corp. engages in the provision of cloud services for recruitment activities. Its cloud products include SONAR, Compass, Sniping and CREATIVE. The company was founded by Takashi Yoshida in May 2013 and is headquartered in Tokyo, Japan.
1
| Subsidiary | Packaged Software | 1 |
82VS
1
| Subsidiary | Investment Managers | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Victor Stone via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
IBM | Packaged Software | Corporate Officer/Principal | |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Hospital/Nursing Management | Director/Board Member | |
GSK PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Investment Officer | |
OBIC CO.,LTD. | Information Technology Services | Director/Board Member | |
Abingworth LLP
Abingworth LLP Investment ManagersFinance Abingworth LLP (Abingworth) is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. Abingworth LLP became part of The Carlyle Group Inc. (NASDAQ: CG) on 3rd August 2022. | Investment Managers | Consultant / Advisor Private Equity Investor Consultant / Advisor Private Equity Investor | |
University of Oxford | College/University | Doctorate Degree Graduate Degree Graduate Degree | |
University of Cambridge | College/University | Corporate Officer/Principal Graduate Degree | |
JAPAN ASIA INVESTMENT CO., LTD. | Investment Managers | Corporate Officer/Principal | |
Pappas Capital LLC
Pappas Capital LLC Investment ManagersFinance Pappas Capital LLC (Pappas Ventures) is a venture capital firm founded in 1994 by Art M. Pappas. The firm is headquartered in Durham, North Carolina. | Investment Managers | Private Equity Analyst | |
University of Utah | College/University | Doctorate Degree | |
The College of New Jersey | College/University | Undergraduate Degree | |
The Johns Hopkins University | College/University | Graduate Degree | |
LaSalle University | College/University | Undergraduate Degree Undergraduate Degree | |
Union College (New York) | College/University | Undergraduate Degree | |
University of British Columbia | College/University | Undergraduate Degree | |
Simon Fraser University | College/University | Masters Business Admin | |
Moscow State University Lomonosov | College/University | Undergraduate Degree Masters Business Admin | |
Mitsubishi UFJ Securities Holdings Co., Ltd.
Mitsubishi UFJ Securities Holdings Co., Ltd. Investment Banks/BrokersFinance Mitsubishi UFJ Securities Co. Ltd. provides securities services including dealing, brokering, underwriting, and distribution. It also provides management and investment, venture capital, real estate leasing, insurance agency, and data processing systems development. The company was founded on March 4, 1948 and is headquartered in Tokyo, Japan. | Investment Banks/Brokers | Comptroller/Controller/Auditor | |
Saitama University | College/University | Doctorate Degree | |
Mitsubishi UFJ Morgan Stanley Securities Co., Ltd.
Mitsubishi UFJ Morgan Stanley Securities Co., Ltd. Investment Banks/BrokersFinance Mitsubishi UFJ Morgan Stanley Securities Co., Ltd. (MUMSS) is an independent securities brokerage firm headquartered in Tokyo, Japan. The firm was founded in 1948 through a joint venture between Mitsubishi UFJ Securities Holdings Co. Ltd. and Morgan Stanley Japan Holdings Co. Ltd. MUMSS offers domestic retail brokerage services to corporate and institutional clients. | Investment Banks/Brokers | Comptroller/Controller/Auditor | |
AXEL MARK INC. | Advertising/Marketing Services | Director/Board Member Director/Board Member | |
SBI Savings Bank Co., Ltd.
SBI Savings Bank Co., Ltd. Major BanksFinance SBI Savings Bank Co., Ltd. is engaged in providing banking services. It supports credit association. The company was founded on October 20, 1971 and is headquartered in Seoul, South Korea. | Major Banks | Director/Board Member | |
REGiMMUNE Corp.
REGiMMUNE Corp. Pharmaceuticals: MajorHealth Technology REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan. | Pharmaceuticals: Major | Director/Board Member | |
ALBERT | Packaged Software | Director/Board Member Director/Board Member | |
Genisphere LLC
Genisphere LLC Electronic Equipment/InstrumentsElectronic Technology Genisphere LLC manufactures kits and reagents used for the ultra-sensitive detection of nucleic acids and proteins. Its solutions are primarily based on its proprietary whole transcriptome RNA Amplification processes, miRNA labeling methodologies, and 3DNA Dendrimer Nanotechnology. The firm's combined technologies permit the interrogation and ultra-sensitive detection of a wide range of biomolecules on a variety of detection platforms, including microarrays, flow and bead based assays, ELISAs, lateral flow assays and RNA sequencing. The company was founded in 1997 and is headquartered in Hatfield, PA. | Electronic Equipment/Instruments | Director/Board Member Director/Board Member | |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
SMBC Venture Capital KK
SMBC Venture Capital KK Investment ManagersFinance SMBC Venture Capital KK (SMBC Venture Capital) is a Private Equity firm, a subsidiary of Sumitomo Mitsui Banking Corp., itself a subsidiary of publicly traded company Sumitomo Mitsui Financial Group, Inc. (TK:8316) founded in 2005. The firm is headquartered in Tokyo. | Investment Managers | Private Equity Investor | |
Corporate Fuel Partners LLC
Corporate Fuel Partners LLC Investment ManagersFinance Corporate Fuel Partners LLC (Corporate Fuel Partners) is a private equity subsidiary of Corporate Fuel Advisors LLC Founded in 2005. The firm is headquartered in New York. | Investment Managers | Private Equity Investor | |
The University of North Carolina at Charlotte | College/University | Masters Business Admin | |
The University of Chicago Booth School of Business | College/University | Masters Business Admin Masters Business Admin | |
Miyako Capital KK
Miyako Capital KK Investment ManagersFinance Miyako Capital KK (Miyako Capital) is an Independent Private Equity/Venture Capital firm founded in 2013 by Satoshi Yamaguchi and Hiroaki Okahashi. Miyako Capital KK is headquartered in Kyoto. | Investment Managers | Private Equity Investor | |
Natori Law Office | Corporate Officer/Principal | ||
XILIO THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Gammadelta Therapeutics Ltd.
Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom. | Biotechnology | Chairman Director/Board Member | |
StrideBio, Inc.
StrideBio, Inc. BiotechnologyHealth Technology Stridebio, Inc. focuses on creating and developing novel adeno-associated viral vector technologies. The company was founded by Aravind Asokan, Mavis Agbandje-McKenna and Patrick Ritschel and is headquartered in Durham, NC. | Biotechnology | Director/Board Member | |
Palleon Pharmaceuticals, Inc.
Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | Miscellaneous Commercial Services | Director/Board Member | |
CellAxia, Inc.
CellAxia, Inc. Pharmaceuticals: MajorHealth Technology CellAxia, Inc. is a Japanese company that engages in research and development, manufacturing, and selling of pharmaceutical products. The company is based in Tokyo, Japan. The company was founded in 2017 by Makoto Seki. | Pharmaceuticals: Major | Director/Board Member | |
4BIO Ventures Management Ltd.
4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor Private Equity Investor | |
Redpin Therapeutics, Inc.
Redpin Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Redpin Therapeutics, Inc. operates as a biotechnological platform which enables targeted regulation of neuronal activity in brain to achieve treatment and control of CNS circuit and other disorders. The company was founded by Elma S. Hawkins, Jeffrey Friedman, Scott Sternson Michael Kaplitt, Sarah Stanley and Jonathan Dordick in 2017 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Director/Board Member Chairman | |
RBG Partners KK
RBG Partners KK Investment ManagersFinance RBG Partners KK engages in the operation and management of investment business partnership assets. It also deals with the acquisition and holding of securities and offers consulting services for company diagnosis and investment planning. The company was founded on October 2, 2018 and is headquartered in Yokohama, Japan. | Investment Managers | Director/Board Member | |
Catamaran Bio, Inc.
Catamaran Bio, Inc. Financial ConglomeratesFinance Catamaran Bio, Inc. provides investment services. The company is headquartered in Delaware. | Financial Conglomerates | Corporate Officer/Principal Director/Board Member | |
Transine Therapeutics Ltd.
Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Egle Therapeutics SAS
Egle Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Egle Therapeutics SAS is a biotech company based in Paris, France. Egle Therapeutics develops first-in-class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases. The French company leverages its translational-based target discovery platform to unveil novel therapeutic Treg targets and computationally designed immunocytokines acting as antagonists or as selective Treg-agonists. The company was founded in 2020 by Luc Boblet, a serial biotech entrepreneur, and Dr. Eliane Piaggio, a renowned immunologist. | Miscellaneous Commercial Services | Director/Board Member | |
Xilio Therapeutics LLC
Xilio Therapeutics LLC Pharmaceuticals: MajorHealth Technology Part of Xilio Therapeutics, Inc., Xilio Therapeutics LLC develops cancer biopharmaceuticals. The company is based in Waltham, MA. The CEO of the company is René Russo. | Pharmaceuticals: Major | Director/Board Member | |
Hc Bioscience, Inc.
Hc Bioscience, Inc. Pharmaceuticals: MajorHealth Technology hC Bioscience, Inc. is a biotech company based in Cambridge, MA and has subsidiaries in the United States. A single trna therapy has the potential to treat many diseases, regardless of the gene or location of the mutation. hC Bioscience is dedicated to improving the lives of patients by developing first-in-class trna-based therapeutics that target protein dysfunction. The company's innovative approach to precision protein editing has the potential to treat genetically defined conditions that account for 10-15% of all human diseases. The lead platform in development is directed at restoring protein function in diseases caused by nonsense mutations or premature termination codons (PTCs). The company was founded in 2021 by Leslie J. Williams, who has been the CEO since then. | Pharmaceuticals: Major | Director/Board Member | |
Larkspur Biosciences, Inc.
Larkspur Biosciences, Inc. BiotechnologyHealth Technology Larkspur Biosciences, Inc. is a company based in Watertown, MA that is pioneering a new wave in cancer therapy. Larkspur’s approach targets cancer-intrinsic factors that tumors use to escape immune detection and control to develop new treatment options for patients who cannot be helped by current therapies. The company is advancing first-in-class programs designed to eliminate tumor “bottlenecks” that drive immune evasion in colorectal cancer (CRC) and beyond. Larkx, the company’s proprietary bioinformatics platform, couples machine learning with tumor genetics to discover immune evasion pathways that originate in the tumor and enrich clinical strategies for potential responders to its therapies across multiple types of cancer. The company was founded by Nathanael S. Gray, Vijay Kumar Kuchroo, and Lewis Clayton Cantley. The CEO is Catherine Sabatos-Peyton. | Biotechnology | Director/Board Member |
Statistics
International
United States | 25 |
Japan | 14 |
United Kingdom | 8 |
Canada | 3 |
Iceland | 2 |
Sectoral
Health Technology | 14 |
Consumer Services | 14 |
Finance | 13 |
Commercial Services | 7 |
Technology Services | 4 |
Operational
Director/Board Member | 132 |
Corporate Officer/Principal | 32 |
Independent Dir/Board Member | 23 |
Private Equity Investor | 23 |
Undergraduate Degree | 14 |
Most connected contacts
Insiders | |
---|---|
Ed Mathers Mathers | 47 |
Timothy Haines | 36 |
Brian McVeigh | 15 |
Peter Goodfellow | 13 |
Jayson Punwani | 12 |
Robbie Woodman | 12 |
Joseph Truitt | 10 |
Dmitry Kuzmin | 9 |
Yury Kukushkin | 9 |
Sacha Mann | 9 |
Takashi Ejiri | 8 |
Lauren Mifflin | 7 |
S. Rouan | 7 |
Russ Fein | 7 |
Miles Gerson | 6 |
- Stock Market
- Insiders
- Victor Stone
- Company connections